Azithromycin and the risk of cardiovascular death [4]

New England Journal of Medicine

Volumn 367, Issue 8, 2012, Pages 773-774

  Albert, Richard K ^a   Connett, John ^b   Woodruff, Prescott G ^c  

^a DENVER HEALTH AND HOSPITAL AUTHORITY   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DRUG WITHDRAWAL; HEART DEATH; HEART RATE; HUMAN; LETTER; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 84865306933     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1207269     Document Type: Letter

References (4)

1. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365:689-98. [Erratum, N Engl J Med 2012;366:1356.]
2. Hannan EL. Randomized clinical trials and observational studies: guidelines for assessing respective strengths and limitations. JACC Cardiovasc Interv 2008;1:211-7.
3. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. Health Technol Assess 2003;7:1-173.
4. Bosco JLF, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol 2010;63:64-74.